Every material Form 8-K GYRE THERAPEUTICS, INC. has filed with the SEC since September 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Gyre Therapeutics reported third-quarter 2026 revenue of $32.9 million, up 1% from $32.7 million a year earlier, but swung to a net loss of $2.5 million from net income of $1.9 million. The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million, while nine-month results showed a larger loss and lower revenue, which matters to shareholders weighing the cost of the Cullgen acquisition and clinical spending.
Q3 2026 revenue was $32.9 million versus $32.7 million in Q3 2025; ETUARY sales were $31.4 million.
Q3 GAAP basic EPS was $(0.04), compared with $0.01 a year earlier.
Nine-month net loss was $35.3 million versus net income of $4.6 million; nine-month revenue was $86.5 million versus $93.0 million.
Total cash, deposits and certificates of deposit were $98.8 million at September 30, 2026, down from $116.1 million at December 31, 2025.
Gyre Therapeutics entered into employment agreements on October 16, 2026 with CEO Ying Luo and CFO Thomas Eastling, under which both will continue in their current roles. The filing sets out their base salaries, bonus targets and severance terms, including enhanced payments if employment ends within three months before or twelve months after a change of control.
Dr. Ying Luo: annual base salary of $500,000 and a 2026 bonus target of $150,000
Thomas Eastling: annual base salary of $339,066 and a 2026 bonus target of $70,000
Change-of-control severance for both includes a lump sum of base salary plus target annual bonus and up to twelve months of COBRA premium reimbursement
Gyre Therapeutics made an updated corporate presentation available on its website on September 1, 2026, and furnished it as Exhibit 99.1 to a Form 8-K under Item 7.01 (Regulation FD Disclosure). The deck restates the company's FY26 total revenue guidance for ETUARY of $100.5M-$111M and a potential F351 launch in early 2027, and the filing itself reports no new financial results.
Presentation made available on the company's website on September 1, 2026; dated September 2026 and furnished as Exhibit 99.1.
ETUARY FY26 total revenue guidance shown as $100.5M-$111M.
F351 (hydronidone) NDA accepted by China's NMPA in May 2026, with potential launch after the NMPA decision in early 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GYRE THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →